Europeiska unionen - litauiska - EMA (European Medicines Agency)

sanofi b.v. - sevelameras - renal dialysis; hyperphosphatemia - visi kiti gydomieji produktai - renagel is indicated for the control of hyperphosphataemia in adult patients receiving  haemodialysis or peritoneal dialysis. renagel should be used within the context of a multiple therapeutic approach, which could include calcium supplements, 1,25 - dihydroxy vitamin d3 or one of its analogues to control the development of renal bone disease.

Europeiska unionen - litauiska - EMA (European Medicines Agency)

sanofi winthrop industrie - insulin glargine, lixisenatide - cukrinis diabetas, 2 tipas - narkotikai, vartojami diabetu - suliqua is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to metformin with or without sglt-2 inhibitors.

Europeiska unionen - litauiska - EMA (European Medicines Agency)

sanofi winthrop industrie - aflibercept - kolorektaliniai navikai - antinavikiniai vaistai - metastazavusio kolorektalinio vėžio gydymas (mcrc).

Europeiska unionen - litauiska - EMA (European Medicines Agency)

sanofi winthrop industrie - sarilumabas - artritas, reumatas - imunosupresantai - kevzara kartu su metotreksatu (mtx) yra skirtas gydyti vidutinio sunkumo ar sunkiu aktyviu reumatoidiniu artritu (ra) suaugusiems pacientams, kurie buvo nepakankamai veiksmingas, arba jie jų netoleruoja vieno ar daugiau ligos eigą kovos reumatinės vaistus (lmarv). kevzara gali būti skiriamas kaip monoterapija mtx netoleravimo atveju arba kai gydymas mtx yra netinkamas.

Europeiska unionen - litauiska - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumabas - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - dermatito veikėjai, išskyrus kortikosteroidus - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Litauen - litauiska - SMCA (Valstybinė vaistų kontrolės tarnyba)

sanofi pasteur - difterijos anatoksinas/stabligės anatoksinas/kokliušo antigenai: kokliušo anatoksinas/filamentinis hemagliutininas/pertaktinas/fimbriae 2-ojo ir 3-iojo tipo - injekcinė suspensija užpildytame švirkšte - >=2 µg/>=20 µg/2,5 µg/5 µg/3 µg/5 µg/dozėje; >=2 tv/>=20 tv/2,5 µg/5 µg/3 µg/5 µg/dozėje; >=2 tv/>=20 tv/2,5 µg/5 µg/3 µg/ - pertussis, purified antigen, combinations with toxoids

Litauen - litauiska - SMCA (Valstybinė vaistų kontrolės tarnyba)

sanofi pasteur - inaktyvuotas hepatito a virusas (gbm padermė) - injekcinė suspensija - 160 v/0,5 ml - hepatitis a, inactivated, whole virus

Litauen - litauiska - SMCA (Valstybinė vaistų kontrolės tarnyba)

sanofi winthrop industrie - hidrochlorotiazidas - tabletės - 25 mg - hydrochlorothiazide

Litauen - litauiska - SMCA (Valstybinė vaistų kontrolės tarnyba)

sanofi pasteur - Žmogaus pasiutligės imunoglobulinas - injekcinis tirpalas - >=150 tv/ml; >=150 tv/ml - rabies immunoglobulin

Litauen - litauiska - SMCA (Valstybinė vaistų kontrolės tarnyba)

sanofi pasteur s.a. - išgrynintas difterijos anatoksinas/išgrynintas stabligės anatoksinas - injekcinė suspensija - >=2 tv/>=20 tv/dozėje; >=2 tv/>=20 tv/dozėje - tetanus toxoid, combinations with diphtheria toxoid